Spineart announces the full-market launch of its SCARLET® AC-Ti secured anterior cervical cage in the United States.
Following 510(k) clearance in May 2024, SCARLET® AC-Ti has been extensively evaluated by clinical experts and this launch signifies the Company’s continued commitment to US product expansion.
After implanting more than 50 SCARLET® AC-Ti, Zakhria Belasher, MD* from Insight Surgical Hospital shared, “With SCARLET® AC-Ti, I have observed consistent performance, reliable standalone stability—with no instances of postoperative dysphagia. Its intuitive design, porous titanium structure, and optimized screw angulation promotes early fusion while enhancing patient recovery and surgical efficiency, making it a seamless and trusted component of my anterior cervical fusion practice!”
Alessia Erlingher, Chief Commercial Officer at Spineart said, „With SCARLET® AC-Ti, we’re bringing an exciting new advancement to the ACDF segment in the US, reinforcing our ongoing commitment to innovation. Following the highly promising results from the initial release phase, we are thrilled to now make this latest technology available to more surgeons.”
SCARLET® AC-Ti builds on a decade of experience with the SCARLET® system and utilizes our Ti-LIFE technology, a proprietary additive manufacturing process, providing a porous structure that closely mimics the trabecular bone structure. Our secured anterior cervical cage is known for its redefined anatomical shape, integrated screw guides and anti-backout mechanism.
To learn more about SCARLET® AC-Ti, contact your local sales representative or complete the form: https://www.spineart.com/us/contact/
*Dr. Belasher is a paid consultant of Spineart. His statements represent his own opinions based on personal experience and are not necessarily those of Spineart. Individual results may vary.